Compare Nuwellis Inc (NUWE) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Workiva Inc — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Workiva Inc trades at $73.19 (market cap $3.89B). The key difference: Workiva Inc is far larger — about 1768.2× Nuwellis Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Workiva Inc for 21 Days on average.
| NUWE | WK | |
|---|---|---|
Market Cap | $2.20M | $3.89B |
Volume | 121,544 | 1,378,359 |
Sector | Health | Technology |
52-Week High | $146.65 | $93.31 |
52-Week Low | $0.68 | $44.31 |
Typical Hold Time | 26 Days | 21 Days |
Enterprise Value | -$1.52M | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Workiva (WK) trades at $71.53, up 1.95% with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and an $86 price target representing 20% upside potential from current levels.
The outlook remains positive with continued earnings growth and AI-driven product expansion driving potential upside. Key risks include high valuation multiples (P/E 85.15) and competitive pressures in the regulatory technology space. The stock's technical positioning near support at $71 suggests near-term stability, while fundamental improvements support longer-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
